Amphastar files to sell $300M of convertible senior notes due 2029

Amphastar Pharmaceuticals announced that it intends to offer, subject to market conditions and other factors, $300M aggregate principal amount of convertible senior notes due 2029 in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Amphastar also intends to grant the initial purchasers of the notes an option to purchase up to an additional $45M aggregate principal amount of the notes.